The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
LHRH-Targeted Nanogels as a Delivery System for Cisplatin to Ovarian Cancer
Open accessAbstract
Targeted drug delivery using multifunctional polymeric nanocarriers is a modern approach for cancer therapy. Our purpose was to prepare targeted nanogels for selective delivery of chemotherapeutic agent cisplatin to luteinizing hormone-releasing hormone (LHRH) receptor overexpressing tumor in vivo. Building blocks of such delivery systems consisted of innovative soft block copolymer nanogels with ionic cores serving as a reservoir for cisplatin (loading 35%) and a synthetic analogue of LHRH conjugated to the nanogels via poly(ethylene glycol) spacer. Covalent attachment of (D-Lys6)-LHRH to nanogels was shown to be possible without loss in either the ligand binding affinity or the nanogel drug incorporation ability. LHRH-nanogel accumulation was specific to the LHRH-receptor positive A2780 ovarian cancer cells and not toward LHRH-receptor negative SKOV-3 cells. The LHRH-nanogel cisplatin formulation was more effective and less toxic than equimolar doses of free cisplatin or untargeted nanogels in the treatment of receptor-positive ovarian cancer xenografts in mice. Collectively, the study indicates that LHRH mediated nanogel-cisplatin delivery is a promising formulation strategy for therapy of tumors that express the LHRH receptor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Successful targeted delivery of these drug-loaded micelles to the tumors using tumor-specific ligands attached to the micelle outer PEG chains were also described [179–181].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [180]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mosmann, T. (1983) · Journal of Immunological Methods · doi:10.1016/0022-1759(83)90303-4 · Cited by 56,104
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review
Maeda, H., Wu, J., Sawa, T., Matsumura, Y., & Hori, K. (2000) · Journal of Controlled Release · doi:10.1016/s0168-3659(99)00248-5 · Cited by 6,565
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
The dawning era of polymer therapeutics
Duncan, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1088 · Cited by 3,269
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
TORCHILIN, V (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.009 · Cited by 1,273
Low, P. S., Henne, W. A., & Doorneweerd, D. D. (2008) · Accounts of Chemical Research · doi:10.1021/ar7000815 · Cited by 1,173
Arany, I., & Safirstein, R. L. (2003) · Seminars in Nephrology · doi:10.1016/s0270-9295(03)00089-5 · Cited by 906
Schally, A. V., Arimura, A., Kastin, A. J., Matsuo, H., Baba, Y., Redding, T. W., Nair, R. M. G., Debeljuk, L., & White, W. F. (1971) · Science · doi:10.1126/science.173.4001.1036 · Cited by 770
Research works printed but not linked: 2
- Oberoi H. S., 2012, Chemother. Res. Pract., 2012, 905796
- Segal E., 1985, Cancer Res., 45, 492
Cited by
Hwang, D., Ramsey, J. D., & Kabanov, A. V. (2020) · Advanced drug delivery reviews · doi:10.1016/j.addr.2020.09.009 · Cited by 699
Self-citationNanogels: An overview of properties, biomedical applications and obstacles to clinical translation
Soni, K. S., Desale, S. S., & Bronich, T. K. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.009 · Cited by 683
“folate or LHRH peptide), tumor growth inhibition could be even further enhanced [85,86,97].”
BackgroundSelf-citationRecent Advances in Nanoparticle-Based Cancer Drug and Gene Delivery
(2018) · Advances in Cancer Research · doi:10.1016/bs.acr.2017.11.003 · Cited by 288
“These nanogels were less toxic and showed enhanced antitumor activity (Nukolova et al., 2013).”
BackgroundNanogels for delivery, imaging and therapy
Sivaram, A. J., Rajitha, P., Maya, S., Jayakumar, R., & Sabitha, M. (2015) · WIREs Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1328 · Cited by 173
Can nanomedicines kill cancer stem cells?
Zhao, Y., Alakhova, D. Y., & Kabanov, A. V. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.016 · Cited by 137
Self-citation
Metadata
- Authors
- Nukolova, N. V., Oberoi, H. S., Zhao, Y., Chekhonin, V. P., Kabanov, A. V., & Bronich, T. K.
- Affiliations
- Lomonosov Moscow State University (RU)
- Nebraska Medical Center (US)
- Pirogov Russian National Research Medical University (RU)
- Corresponding author
- Kabanov, Alexander V.
- Bronich, Tatiana K.
- ORCID
- Venue
- Molecular Pharmaceutics
- Publisher
- American Chemical Society (ACS)
- Published
- 2013-08-30
- Volume
- 10
- Issue
- 10
- Pages
- 3913-3921
- ISSN
- 1543-8384 (ISSN-L)
- 1543-8392
- PMC
- PMC3809768
- OpenAlex
- W2070912023
- Cited by
- 63
- References
- 32
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 5 · 2023: 8 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 6 · 2018: 6 · 2017: 2 · 2016: 8 · 2015: 8 · 2014: 4 · 2013: 1
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular Pharmaceutics (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA116590, R01CA116590)
- National Institute of General Medical Sciences (P20GM103480)
- National Center for Research Resources (P20RR021937)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Keywords
- nanogels, cisplatin, ovarian cancer, luteinizing hormone-releasing hormone receptor, polyethylene glycol spacer, A2780 cells, SKOV3 cells, xenografts, chemotherapy toxicity
- MeSH terms
- Nanogels, Animals, Antineoplastic Agents, Cisplatin, Female, Flow Cytometry, Humans, Mice, Nude, Ovarian Neoplasms, Polyethylene Glycols, Polyethyleneimine, Drug Delivery Systems, Microscopy, Confocal, Cell Line, Tumor, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: LHRH-Targeted Nanogels as a Delivery System for Cisplatin to Ovarian Cancer. https://app.cochat.ai/papers/10.1021/mp4003688
- The paper
- Nukolova, N. V., Oberoi, H. S., Zhao, Y., Chekhonin, V. P., Kabanov, A. V., & Bronich, T. K. (2013). LHRH-Targeted Nanogels as a Delivery System for Cisplatin to Ovarian Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/mp4003688
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.